Introduction
============

Dengue is a mosquito-borne disease caused by dengue viruses from the *Flaviviridae* family [@B1],[@B2]*.*It is a disease affecting an estimated 3.97 billion people in over 128 endemic countries, including Malaysia [@B3]. It is described as a dynamic febrile illness which can manifests as self-limiting mild fever or the more severe life-threatening forms with presentation of plasma leakage, hemorrhage or severe multi-organ impairments. A number of mechanisms have been forwarded to explain the pathogenesis of severe dengue, including antibody-dependent enhancement (ADE) of virus infection [@B4], [@B5], overwhelming memory T cell activation [@B6] and exaggerated pro-inflammatory cytokine responses [@B7], [@B8] leading to the more severe or fatal dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS) [@B9]-[@B11].

In recent decades, an uncommon phenomenon of macrophage activation syndrome (MAS) or hemophagocytic syndrome (HS) is increasingly reported in patients with severe dengue. Hemophagocytosis was reported in dengue with multi-organ complications [@B12], observed in severe dengue involving both children and adults [@B13]-[@B15] and associated with dyserythropoiesis [@B16]. MAS is a severe systemic inflammatory condition due to excessive activation and proliferation of T cells and well-differentiated macrophages. The hyperactivated but dysregulated immune responses lead to overwhelming inflammatory responses resulting in non-remitting high fever, hepatomegaly and splenomegaly, lymphadenopathy, haemorrhage and central nervous system dysfunction [@B17]. Diagnostic features of macrophage activation syndrome include hyperferritinemia (above 10000 µg/L), cytopenia, coagulopathy, abnormal liver function tests, hypertriglyceridemia, hypoalbuminemia, hyponatremia, hemophagocytosis and elevated serum sCD25 and sCD16 levels [@B17]-[@B21]. Complications associated with MAS can be fatal. It is the most common underlying presentation of systemic juvenile idiopathic arthritis (sJIA) [@B22]-[@B24]. Presence of hemophagocytosis activity and increased CD163 staining of the bone marrow are among some of the histopathological features of MAS and the best evidence for disease prognosis [@B25]. There have been several reported cases of hemophagocytosis in dengue with extremely high serum ferritin level [@B12], [@B14], [@B26], [@B27]. Markedly elevated level of ferritin has been used as a clinical biomarker for severe dengue, and is considered as one of the most important serum biomarker for dengue disease [@B28], [@B29]. Meanwhile, CD163 is an important macrophage activation marker as its expression and secretion was reported in several infectious diseases including malaria, hepatitis C and HIV [@B30]-[@B35] but there was no previous report on dengue.

Given the close resemblance of a number of clinical features of MAS and severe dengue [@B26], and the observation of hemophagocytosis activity in the bone marrow in dengue cases [@B13], [@B14], [@B16], [@B27], further understanding of the relationship between MAS and dengue immunopathogenesis especially in severe dengue disease is warranted. This is the first study that examined the levels of important biomarkers of MAS in patients with dengue fever and severe dengue.

Materials and methods
=====================

Study Approval
--------------

This study was approved by the Medical Ethics Committee of the University Malaya Medical Centre (Ethics No. 908.9). Written informed consent was obtained from patients to authorize their participation in the study. This study conformed to the Declaration of Helsinki and Malaysian Good Clinical Practice (GCP) guidelines. Blood specimens were obtained from recruited adult patients seen at the infectious disease ward (ID ward) of University of Malaya Medical Centre (UMMC), following 2 to 7 days of fever between year 2012 and 2013. Two hundred eight patients\' clinically- and laboratory-confirmed with dengue were recruited. Confirmation of dengue was based on the detection of dengue specific IgM antibody or dengue non-structural protein 1 (NS1) antigen or dengue specific IgG antibody. Clinical diagnosis of the disease was based on the 2009 World Health Organization (WHO) revised dengue classification. Sera of 48 healthy adult volunteers served as healthy control. Blood specimens were obtained into two vacutainer tubes (BD Biosciences, USA). Blood were collected into EDTA-containing tube for immunostaining while serum separator tube (SST) was used for cytokine assays, as well as for NS1 antigen, dengue IgM and dengue IgG detection. Blood from SST tube was initially spun at 1200xg for 10 minutes. Sera were harvested and kept in -80ºC, until needed.

Detection of Dengue IgM, IgG Antibodies and NS1 Antigen
-------------------------------------------------------

Dengue specific IgM antibody and IgG antibody detection was performed using ELISA (SD Standard Diagnostics Inc., Korea) and dengue NS1 antigen detection was performed using the Dengue NS1 Antigen Strip (Bio-Rad, Hercules, California).

Membrane-Bound CD163 (mCD163) Immunostaining
--------------------------------------------

EDTA blood (200µL) was used for immunostaining. Whole blood was stained with 10 µL of both mouse anti-human CD14 FITC (clone MɸP9 ) and mouse anti-human CD163 PE (clone GH1/61) (Becton Dickinston, USA) and incubated for 30 minutes in the dark at room temperature. The stained whole blood was lysed with 2 mL of FACS lysing buffer (Becton Dickinston, USA). The lysed blood was then spun at 500xg for 4 minutes. The supernatant was discarded and the pellet was washed with 2 mL of FACS buffer containing 1xPBS, 2% foetal bovine serum and sodium azide (1^st^ Base, Singapore; Gibco, USA; Sigma Aldrich, USA) [@B36]. The pellet was re-suspended with FACS buffer prior for analysis with FACS Canto II (Becton Dickinston, USA). Samples acquisition from FACS Canto II was performed following the manufacturer\'s protocol with only minor modifications [@B37]. Data were analysed using BD FACSDiva version 6.1.2 software (BD Bioscience, USA).

Quantitation of Soluble Serum Biomarkers
----------------------------------------

Ferritin quantitation was done at the Clinical Diagnostic Laboratory (CDL) of University Malaya Medical Center (UMMC) based on chemiluminescence enzyme immunoassay (CEIA) using ADVIA Centaur^®^ Immunoassay System (Siemens Healthcare Diagnostics, USA). Soluble serum CD163 and CD25 were determined by using ELISA (R&D System, Minneapolis), following manufacturers\' protocol with minor modifications. Mouse anti-human CD163 and CD25 antibody at concentration 2.0 μg/mL were immobilised in 96-well plate in coating buffer (0.05M carbonate-bicarbonate, pH 9.6), blocked with blocking buffer (50mM tris, 0.14M NaCl, 1% BSA, pH 8.0), and then washed with phosphate buffered saline with 0.05% tween-20. Color was developed by adding TMB substrate solution into each well and incubated for 5 minutes for sCD163 and 20 minutes for sCD25 in dark at room temperature. Reaction was stopped by adding 2 M H~2~SO~4~ and the plate was read at wavelength 450nm with correction at 570 nm. A 4-parameter logistic standard curve was generated from the optical density (OD) readings. The detection limit of each soluble protein was as follows: 1.56 ng/mL (sCD163) and 31.25 pg/mL (sCD25).

Statistics
----------

One-way ANOVA test with Bonferroni\'s multiple comparison was performed using GraphPad Prism version 5.01 software. Receiver operating characteristic (ROC) was plotted to determine the predictive validity of a biomarker to forecast impending severe dengue. The value of the area under the ROC curve (AUCs) was calculated to determine the robustness of the test. The AUCs of 0.5-0.69 was considered as poor, 0.7-0.79 as fair, and 0.8-0.89 as good, 0.9-0.99 as excellent and 1.0 as perfect. Data were presented as median (mean ± standard error) and percentage, where applicable. A *P*-value lower than 0.05 was considered significant.

Results
=======

Confirmation and Classification of Dengue Cases
-----------------------------------------------

A total of 208 patients were recruited for the present study. Clinical and laboratory profiles of the patients were shown in Table [1](#T1){ref-type="table"}. There were 20 confirmed severe dengue patients and 188 dengue fever patients determined based on their anti-dengue IgM, dengue antigen NS1 or anti-dengue IgG status. The laboratory confirmation for dengue was performed according to the Centers for Disease Control and Prevention (CDC) guideline (Fig. [1](#F1){ref-type="fig"}) [@B38]. The classification of severe dengue and dengue fever was based on the 2009 WHO revised classification. In brief, dengue fever can present as a mild self-limiting fever or as the more severe forms of the disease with the observation of severe plasma leakage or severe bleeding and multiple organ failures [@B39]. In the present study, the severe dengue group consisted of four patients with plasma leakage, twelve patients had severe organ impairments, one had plasma leakage with organ impairment, one developed plasma leakage with hemorrhage, and two patients had organ impairments and hemorrhage. The control group consisted of 61 healthy volunteers, 48 were serologically negative for dengue IgG whereas the remaining had positive dengue IgG.

Serum Levels of Soluble Ferritin, sCD163 and sCD25 in Severe Dengue Patients
----------------------------------------------------------------------------

The concentrations of the three distinct markers of MAS were shown in Figure [2](#F2){ref-type="fig"}, Serum ferritin was significantly elevated in severe dengue patients when compared to the dengue fever patients and healthy volunteers with median values of 15172.00 µg/L (25758.00 µg/L ± 6857.88) in severe dengue, 4026.50 µg/L (8877.71 µg/L ± 1730.37) in dengue fever and 57.0 µg/L (82.97 µg/L ± 11.20) in healthy volunteers (Fig. [2](#F2){ref-type="fig"}A). The level of sCD163 was significantly higher in the severe dengue group, with a median value of 399.50 ng/mL (781.13 ng/mL ± 254.26) compared to 192.36 ng/mL (338.88 ng/mL ± 42.03) in the dengue fever group and 226.01 ng/mL (237.54 ng/mL ± 14.67) in healthy volunteers (Fig. [2](#F2){ref-type="fig"}B). Significant elevation of sCD25 was observed in the severe dengue group compared to the healthy control group but not with the dengue fever group. The median values sCD25 level were 1490.00 pg/mL (2663.26 pg/mL ± 520.55) in the severe dengue group, 1400.00 pg/mL (1961.52 pg/mL ± 230.82) in the dengue fever group and 221.81 pg/mL (228.49 pg/mL ± 11.79) in healthy volunteers (Fig. [2](#F2){ref-type="fig"}C). In addition, the correlation between the serum level of sCD163 and ferritin among severe dengue patients was examined. A significant correlation was observed between the level of sCD163 and ferritin with correlation coefficient (r) value of 0.72 (Fig. [3](#F3){ref-type="fig"}A). A fair and perfect area under ROC curves (AUC) at 0.72 and 1.00 were observed when the level of sCD163 of the severe dengue group was compared to the dengue fever group (Fig. [3](#F3){ref-type="fig"}B) and against ferritin among severe dengue group, respectively (Fig. [3](#F3){ref-type="fig"}C). This suggests that sCD163 level was directly associated with manifestations of dengue disease and its severity.

Flow Cytometry Immunostaining of Circulating Membrane-Bound CD163 Monocytes
---------------------------------------------------------------------------

CD163 receptor is shed from macrophages and accumulates in the plasma as soluble form upon inflammatory stimulation. To determine the total number of circulating CD163-bearing monocytes in dengue patients, CD163 cells were gated from the total monocytes population (Fig. [4](#F4){ref-type="fig"}A). Approximately 81.9% (80.9% ± 1.15) of the total monocytes from the healthy control group was positive for CD163 with 51.9% (53.8% ± 3.84); 55.6% (53.6% ± 3.10) for the severe dengue and dengue fever group (Fig. [4](#F4){ref-type="fig"}B), respectively. This suggests that in general, there is an overall reduction in the population of CD163 monocytes in dengue infection.

Discussion
==========

Dengue virus infection can results in severe disease that if not treated early can cause deaths. It is currently among the most important mosquito-borne disease worldwide. Presently, there is no specific drug for dengue treatment or an approved vaccine to prevent dengue. Dengue patients are usually treated in the hospital by close monitoring and good supportive care. Most dengue patients recover uneventfully within 5 days following onset of fever. Only less than 10% would develop severe dengue which manifests with severe intravascular leakages, severe organ impairments and severe heamorrhage. To date, there are no specific ways of determining which among the dengue patients would develop severe dengue. A long list of soluble markers which were observed to be elevated in severe dengue patients has been described. Severe dengue tends to present with high levels of cytokines such as IFN-γ, TNF-α, IL1-β, IL-2, IL-6, IL-8, and IL-10 [@B40]-[@B44]. Moreover, high level of TGF-β [@B9], histamine [@B44], [@B45], [@B46], IL-13, IL-7, GM-CSF [@B48], [@B49] have also been described. More recently, extremely high level of serum ferritin was reported in severe dengue patients [@B28], [@B29]. The level of serum ferritin was significantly different in patients with severe dengue with plasma leakage, haemorrhage and shock [@B29].

Hyperferritinemia, specifically above 10000 µg/L, elevated sCD163 and sCD25 levels are the few laboratory diagnostic features of macrophage activation syndrome (MAS) [@B24], [@B38], [@B50]. Results from the present study suggest that high serum ferritin and sCD163 levels occurred in patients with severe dengue. sCD163, in particular, can robustly differentiate severe dengue patients from those with only dengue fever. CD163 found on macrophages is a haemoglobin scavenger receptor and has been widely described to be involved in the clearance of haemoglobin to prevent oxidative stress [@B51], [@B52]. It mediates the internalization of haemoglobin-haptoglobin (Hb-Hp) complexes and sheds its extracellular part into plasma [@B53]. It is known that dengue virus infection produces pro-inflammatory cytokines such as TNF-α, IFN-γ and IL-6 that can further induce the production of important anti-inflammatory cytokines especially IL-10 [@B8], [@B54], [@B55] known to activate monocytes/macrophages that express CD163 [@B53]-[@B59]. The elevated level of sCD163 reflects activation of monocytes/macrophages consistent with MAS in dengue.

Membrane bound CD163 (mCD163) on the other hand, is solely expressed on cells of monocyte-macrophage lineage. The membrane bound CD163 is shed from cells and accumulates in the plasma as soluble form upon exposure to inflammatory stimuli. The expression of mCD163 is inversely correlated to its soluble form. In agreement with a previous report [@B60], increased in sCD163 level in severe dengue patients is inversely correlated to the percentage of monocytes/macrophages expressing mCD163. The percentage of positive mCD163 cells however, was not significantly different between severe dengue and dengue fever patients but was reduced in comparison to healthy controls. Since reduced number of cells expressing mCD163 was also observed in acute dengue patients, this suggests that active shedding of mCD163 takes place even in dengue fever, perhaps to dampen inflammation caused by the infection. Increased level of sCD163 however, is not unique to dengue as it is noted in critically ill patients whom have contracted various inflammatory diseases [@B61]. Nonetheless up-regulation of CD163 is specific to macrophage adaptation towards inflammation shown in hemophagocytosis in bone marrow, independent of underlying diseases [@B62].

In addition to sCD163, sCD25 is secreted by activated T cells. In our study, sCD25 level did not significantly differ between severe dengue patients from those of dengue fever patients. There was a significant difference however, between acute and convalescence phase sera consistent with heightened activation of T cells during the acute phase of the infection.

Severe dengue infection has a tendency of developing haemorrhage involving blood hemolysis [@B63], [@B64] and it is known that blood hemolysis contributes to the accumulation of serum ferritin as well as from damaged cells [@B65]. In addition, activated macrophages also secrete ferritin into plasma although its mechanism is still unknown [@B66]. Since findings from our study showed that both serum ferritin and soluble CD163 level are correlated to each other in severe dengue patients, we suggest that both markers can be used concurrently to discriminate severe dengue patients from the dengue fever patients. The value of the area under the (ROC) curve (AUCs) is a reflection of the overall ability of the test in discriminating severe dengue patients from dengue patients. ROC is used to determine a cutoff value for a clinical test. Here, we showed that analysis of sCD163 levels of the severe dengue group yielded a fair AUC value of 0.72 when tested against sCD163 from the dengue fever group. Moreover, an excellent AUC value of 1.00 was obtained when the sCD163 levels of severe dengue patients were analysed in combination with patients with ferritin levels above 10000 µg/L, supporting the fitness of sCD163 as a differential marker for severe dengue disease. Previously, the use of blood monocyte CD163 as a biomarker for HIV-1 infection and neuroids was reported [@B67]. sCD163 is potentially an important marker to predict impending severe dengue and until an effective drug or vaccine is available for dengue, a good diagnostic marker of severe dengue is crucial to improve management of severe dengue patients.

In summary, two distinct markers of macrophage activation syndrome were investigated in dengue patients. Hyperferritinemia and increased serum sCD163 are shown in the study to be consistent with severe manifestations of dengue. Ferritin and sCD163, hence, could be charted and noted as important markers for monitoring dengue disease progression.
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![Soluble Serum Biomarkers in Dengue. (A) Ferritin, (B) sCD163, (C) sCD25. One-way ANOVA test with Bonferroni\'s multiple comparison was performed using GraphPad Prism version 5.01 software. \**P*\< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001, ns indicates non-significant.](ijmsv13p0179g002){#F2}

![Correlation analysis and the receiver operating characteristic (ROC) curves of sCD163. (A) Correlation of serum ferritin to sCD163 in severe dengue patients, *P*=0.008. (B) ROC curve for sCD163 in severe dengue group in comparison to the dengue fever group. A fair area under ROC curves (AUC) at 0.72 was obtained. (C) ROC curve combining sCD163 and ferritin above than 10000 µg/L in the severe dengue group. A perfect AUC score at 1.00 was obtained.](ijmsv13p0179g003){#F3}

![Total population of circulating CD163-bearing monocytes in dengue patients. Gating strategy of CD163+ monocytes population originated from total monocytes of peripheral blood (4A). Lower population of CD163+ monocytes is observed in severe dengue (4B) compared to the healthy control group. \**P \<* 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001.](ijmsv13p0179g004){#F4}

###### 

Clinical and laboratory profiles and complications observed among dengue patients.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Dengue Disease   Enrolled\     Laboratory Confirmation of Dengue Disease   \*Complications                   
                   Patients                                                                                    
  ---------------- ------------- ------------------------------------------- ----------------- --------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Severe Dengue    9.6% (20)     Positive (14)                               Positive (10)     Positive (1)    Plasma Leakage (6); Hepatitis (15); Compromising Respiratory (1); Confused CNS (1); Severe Hemorrhage (2)

  Dengue Fever     90.4% (188)   Positive (88)                               Positive (63)     Positive (37)   Vomiting (63); Abdominal Pain (47); Nausea (2); Diarrhea (6); Mucosal Bleeding (8); PV Bleeding (1); Epigastric Pain (1); Gum Bleeding (5); Epistaxis (3); Unspecified Conditions (52)
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Certain patients had more than one complication.
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